193006-39-2

Upstream product

• 288-94-8 1H-tetrazole 
• 4224-69-5 methyl 2-(bromomethyl)propenoate 
• 64847-76-3 3-(hydroxyimino)methylbenzonitrile 
• 52707-53-6 3-cyanobenzaldehyde oxime 
• 231300-35-9 methyl 2-(1H-tetrazol-ylmethyl)acrylate 

Downstream Products

• 1025829-23-5 3-(3-cyano-phenyl)-5-tetrazol-1-ylmethyl-4,5-dihydro-isoxazole-5-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyrimidin-2-yl]-amide 
• 193006-44-9 5-isoxazolecarboxamide, 3-(3-cyanophenyl)-N-<<5-<2'-(tertbutylaminosulfonyl)<1,1'-biphenyl>-4-yl>-4,5-dihydro-5-(1H-tetrazol-1-ylmethyl)->> 

Relevant academic research and scientific papers

ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR Xa INHIBITORS

Isoxazolines, isothiazolines and pyrazolines which are inhibitors of Factor Xa, pharmaceutical compositions containing these compounds, and methods of using these compounds as anticoagulant agents for treatment and prevention of thromboembolic disorders.

Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2

Intravascular clot formation is an important factor in a number of cardiovascular diseases. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa),

ISOXAZOLINE, ISOTHIAZOLINE AND PYRAZOLINE FACTOR XA INHIBITORS

Isoxazolines, isothiazolines and pyrazolines which are inhibitors of Factor Xa, pharmaceutical compositions containing these compounds, and methods of using these compounds as anticoagulant agents for treatment and prevention of thromboembolic disorders. The compounds can be represented by the formula: STR1 where X is O, S or NR 15.